Stoke Therapeutics, Inc. Common Stock

Day range

$24.52 – $25.45

Open

$25.22

Prev close

$25.04

Volume

376.9K

Market cap

$1.62B

Shares out

64.53M

P/E

—

P/S

58.57

P/B

4.68

P/FCF

—

ROE

-60.2%

ROA

-52.8%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Director appointmentSep 25, 2026

  On September 23, 2026, the Board ... appointed Alexander (Bo) Cumbo to serve on the Board as a Class III director, effective September 23, 2026, to fill the vacancy created by Dr. Kaye's resignation. Mr. Cumbo shall hold office for a term expiring at the 2028 Annual Meeting of Stoke's stockholders.

• Public offeringAug 3, 2026

  On August 3, 2026, the Company filed a prospectus supplement (the "Prospectus Supplement") pursuant to Rule 424(b) under the Securities Act with the SEC relating to the offer and sale of up to $200,000,000 of Placement Shares under the Sales Agreement.

• Annual meeting resultsJun 4, 2026

  On June 3, 2026, Stoke Therapeutics, Inc. (the "Company") held its 2026 Annual Meeting of Stockholders, and the following proposals were adopted: 1. Election of three Class I directors, G. Clare Kahn, Ph.D., Adrian Krainer, Ph.D. and Julie Anne Smith, each to serve a three-year term... 2. Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026... 3. Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers.

• Equity compensation grantApr 7, 2026

  In accordance with the Company's 2019 Equity Incentive Plan (the "Plan"), on the effective date of her appointment, Dr. Kahn was granted an initial stock option to purchase 30,782 shares of the Company's common stock, which represents a target grant date fair value of approximately $724,000 as calculated in accordance with ASC 718, and will vest in twelve substantially equal quarterly installments on each quarterly anniversary of the date of grant.

• New auditor engagementMar 27, 2026

  On March 23, 2026, the Audit Committee approved the engagement of Ernst & Young LLP ("EY") as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.

Days to cover

10.2

Short interest

11.51M

Avg volume

1.13M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• A Closer Look at 5 Analyst Recommendations For Stoke Therapeutics
  Benzinga· Jun 28, 2024
• Analyst Expectations For Stoke Therapeutics's Future
  Benzinga· May 6, 2024
• Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates
  Zacks Investment Research· May 6, 2024
• Earnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to Decline
  Zacks Investment Research· Apr 29, 2024
• Earnings Preview: Stoke Therapeutics, Inc. (STOK) Q1 Earnings Expected to Decline
  Zacks Investment Research· Apr 25, 2024